Medtronic reported first-quarter fiscal 2027 revenue of $9.756 billion, topping the Wall Street consensus of $9.54 billion by roughly 2.3 percent. Adjusted diluted EPS came in at $1.45, six cents above the $1.39 estimate. GAAP diluted EPS was $1.14, up more than 40 percent year-over-year.
The headline beat requires a critical read. The quarter ran 14 weeks instead of the standard 13, and Medtronic estimates that extra fiscal week added approximately $570 million to first-quarter organic revenue. Strip that out and the underlying organic growth rate drops materially from the reported 13.7 percent—a distinction the company disclosed in its press release.
All four business segments posted growth. Cardiovascular, the company's largest, grew 19.5 percent. Diabetes grew 16.9 percent. Neuroscience rose 10.3 percent and Medical Surgical added 10 percent. That breadth matters: Medtronic has historically been criticized for uneven segment performance, and a quarter where every division grew double digits removes that overhang.
Based on Q1 results, Medtronic raised its full-year FY27 organic revenue growth guidance to 7.25 percent to 7.75 percent, up from 6.75 percent to 7.25 percent. Full-year adjusted revenue is now guided at $38.9 billion to $39.2 billion, above the prior Street consensus of $38.83 billion. Full-year adjusted EPS guidance moved to $5.94 to $6.00—the midpoint of $5.97 is essentially in line with prior consensus, which limits the EPS upside argument for the full year even as revenue guidance steps up.
MDT shares rose 6.16 percent following the release, trading at $96.23 with volume running at 34.4 times the stock's average daily pace.
The quarter included several product and business development moves. Medtronic received CE Mark expansion for its Affera mapping and ablation system in Europe. The FDA cleared Touch Surgery Aide, a surgical guidance tool. The company completed acquisitions of Scientia Vascular and SPR Therapeutics, formed a strategic partnership with Cornerstone Robotics, and invested in Pi-Cardia.
The most consequential unresolved item is the planned separation of the Diabetes segment. Medtronic has not finalized the transaction structure and is considering a split-off, a public offering, or a combination of the two, with a split-off currently the preferred path. A split-off would give existing MDT shareholders the option to exchange their shares for shares in the new Diabetes entity, which changes the capital structure math. Until Medtronic announces the structure, the economics for current shareholders remain open.
The Diabetes segment grew 16.9 percent in Q1, the second-fastest among the four units, which adds complexity to the separation calculus. A fast-growing business being carved out at an undefined valuation is a variable that sell-side models cannot yet price cleanly. The separation decision is the next material catalyst for MDT.
On valuation, MDT at $96.23 trades at roughly 16 times the midpoint of its new FY27 adjusted EPS guidance of $5.97. That is a discount to large-cap medical device peers like Abbott Laboratories and Boston Scientific, both of which trade above 20 times forward earnings. The discount has persisted for years, partly because of the Diabetes drag and partly because of Medtronic's slower organic growth history. A sustained 7-plus percent organic growth rate—adjusted for the extra fiscal week—would challenge that discount.
Once Medtronic announces whether it proceeds via split-off, IPO, or hybrid, shareholders will have a concrete basis for assessing how the remaining three segments—Cardiovascular, Neuroscience, and Medical Surgical—are valued on a standalone basis. The Cardiovascular unit alone, growing at 19.5 percent, would command a premium multiple in the current medical device market.
